Clinical significance of using transcranial magnetic therapy in comprehensive non-drug recuperation of neonates with perinatal lesions of central nervous system

The objective was to assess the effectiveness of the use of transcranial magnetic therapy in comprehensive non-drug recuperation of neonates with perinatal injury of the central nervous system. Materials and Methods. Our research involved 214 newborns with corrected age of 30 weeks of gestation and perinatal lesion of the central nervous system. Main group (n=79): neonates underwent standard pharmacotherapy in combination with comprehensive non-drug recuperation (which included dry immersion, music therapy and orolingual massage), and transcranial magnetic therapy. Comparison group (n=74): newborns underwent standard pharmacotherapy in combination with non-drug recuperation. Control group (n=61): infants received conventional pharmacotherapy. Results. In Main group, hyperexcitability syndrome was healed in 60% of infants, and autonomic visceral disorders were cured in 80% of children. CNS depression syndrome signs disappeared in 67% of neonates. A significant (p<0.05) decrease in the resistance index was noticed, along with reduction in elevated peripheral vascular resistance and expansion of physiological reflexes, especially of the oral automatism group. Odds ratio of normalization of oral reflexes by day 10 for Main group vs. Control group was 5.09 with 95% CI [1.8-13.8]; and for Main group vs. Comparison group, it was 3.0 with 95% CI [1.1-8.4]. Normalization of muscle tone and resistance index reduction by day 10 in Main group was observed 8 and 4 times more often, correspondingly, than in Control group. Odds ratios were 8.2 with 95% CI [1.8-16.3] and 4.05 with 95% CI [1.06-9.3], respectively. Conclusion. Non-drug recovery methods in combination with magnetic therapy generated the sedative effect; provided stimulation of respiratory movements and spontaneous motor activity; and contributed to restoring proper reflex action. Hence, they are recommended for inclusion in the perinatal CNS lesion therapy of neonates.